{"nct_id":"NCT05508867","title":"A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-10","start_date":"2022-10-18","start_date_type":"ACTUAL","primary_completion_date":"2025-09-03","primary_completion_date_type":"ACTUAL","completion_date":"2026-01-08","completion_date_type":"ESTIMATED","phases":["PHASE2"],"tickers":["MRK"]}